From Palm-Processing Sidestreams to Microbiome-Informed Nutraceuticals: Phenolic-Rich Palm Residues, Microbial Metabolism, and the Gut-Metabolic Axis in Obesity-A Critical Review

Abstract

Phenolic-rich fractions recovered from oil-palm processing represent an emerging opportunity to connect circular bioeconomy strategies with microbiome-oriented metabolic health interventions. Unlike conventional debates concerning palm oil as dietary fat, this review focuses on non-lipid palm-derived bioactives and their potential interaction with the gut microbiota in obesity. Palm-processing aqueous fractions contain chemically diverse phenolics whose biological activity may depend on gastrointestinal bioaccessibility, microbial biotransformation, and production of metabolites capable of influencing intestinal and systemic physiology. Contemporary evidence supports bidirectional interactions between dietary polyphenols and gut microorganisms, with potential effects on short-chain fatty acids, phenolic microbial metabolites, bile-acid signaling, intestinal permeability, metabolic endotoxemia, inflammation, insulin sensitivity, lipid metabolism, and energy regulation. Palm-specific clinical studies demonstrate the safety and selected cardiometabolic effects of standardized oil palm phenolics, whereas direct evidence connecting palm-derived phenolic interventions to microbiome-mediated improvement of obesity remains limited. An important 2024 palm-residue study used fecal fermentation rather than an oral clinical intervention, highlighting the translational gap between microbial plausibility and demonstrated human efficacy. This review proposes a palm phenolic–microbiome–host axis and argues that future development should progress from generic “phenolic-rich extract” concepts toward chemically fingerprinted, microbiologically stratified, metabolomically verified, precision nutraceuticals. Responders and nonresponders should become a central consideration in future clinical development.